C-reactive protein (CRP) tests are blood tests that are performed to measure C-reactive protein levels. C-reactive protein (CRP) is a protein released by the liver, and its levels rise when the body is inflamed. Infections and disorders that cause inflammation, such as cancers, cardiovascular diseases, arthritis, and others, are detected and tracked using C-reactive tests. This test predicts the risks of a person having a heart attack or a stroke. The rising prevalence of cardiovascular diseases, as well as the sheer volume of tests needed worldwide, is the major driver of this market.
Increased research applications, broad target populations, applications in point-of-care testing, and increased global health-care awareness, especially in developing countries, are all positively impacting the market. Researchers’ development of novel strategies for studying the concentration of C-reactive protein offers high-value market growth opportunities.
C反应蛋白检测市场中观察到的关键趋势
政府举措正在推动C反应蛋白检测市场，以鼓励在医疗保健环境中使用POC（护理点）测试。betway体育亚洲版入口近年来，由于其在短时间内产生快速和精确结果的能力，近年来，护理点测试方法已经爆发。此外，用于测量C反应蛋白浓度的创新技术的进步为C反应蛋白研究行业扩张开辟了新的机会。
For instance, in November 2019, researchers developed an impermanent smartphone-based diffusometric immunoassay for determining the C-reactive protein test. The growing prevalence of gastrointestinal diseases along with the subsequent rise in demand for robust disease testing protocols contributes to the market growth to a considerable extent.
C反应蛋白检测市场的区域前景
North America dominates the market owing to the existence of a favorable reimbursement scheme and increasing healthcare expenditure along with rising investment for research activities. For instance, BlueCross BlueShield of North Carolina covers reimbursement for general inflammation testing and provides C-reactive protein testing for the diagnosis of inflammatory diseases.
C-反应蛋白可用于鉴定在东南亚国家正在进行的研究中的细菌和非细菌感染，并且可以用作引导抗生素处方的生物标志物。在东南亚的低疟疾传播国，疟疾-CRP测试的组合被认为是疟疾测试的可行替代品。
Cardiovascular Diseases (CVD) holds the Highest Revenue Share in the Market
心血管疾病发生率的上升由于d the world is one of the major factors that drive demand for C-reactive protein testing. As per the report of the American Heart Association, over 356,000 out-of-hospital cardiac arrest incidences detected in the United States each year, with 90 percent of cases resulting in death. Because of the high occurrence rate, physicians are encouraged to use C-reactive protein testing on a wide scale.
此外，CVD病例的增加促使研究人员进行调查研究，以研究C-反应蛋白检测在CVD中的功能，提高分部收入。例如，根据2019年8月由魏王发布的一项研究，HS-CRP与普利白多功能的比例可以用作早期生物标志物，以预测患者中医院的内部显着不良心脏事件。
对C反应蛋白检测市场的深度洞察by Polaris Market Research:https://www.polarismarketreesearch.com/industry-analysis/c-reectrive-protein-testing-market/request-for-sample.